Alimera : Changing from A Buy to Hold (ALIM, $1.20, Hold)Thursday, November 16, 2017 · 9:55 am |
|
Alimera Sciences: Company Achieves Breakeven Pretax Cash Flow in 2Q, 2017 Despite Slow Unit Demand for Iluvien (ALIM, Buy, $1.50)Monday, August 14, 2017 · 1:17 pm |
|
Alimera Sciences: Iluvien Sales Seem to Have Caught Traction; It Is Time to Buy! (ALIM, Buy, $1.35)Wednesday, June 21, 2017 · 11:01 am |
|
Alimera: Iluvien Sales are Encouraging but the Company is Financially Stressed (ALIM, $1.79, Neutral)Monday, August 8, 2016 · 8:22 am |
|
Comments on Alimera (ALIM, $4.46, Neutral) and pSivida (PSDV, $3.97, Neutral)Saturday, May 23, 2015 · 10:12 am |
|
Alimera Sciences: Some Thoughts on the Upcoming US Launch of Iluvien (ALIM, Neutral, $5.29)Wednesday, February 18, 2015 · 11:48 am |
|
Alimera Sciences: Will The Launch of Iluvien Be Disappointing to Investors? (ALIM, Neutral, $5.53)Saturday, January 24, 2015 · 11:45 am |
|
pSivida: Previewing the October 17th PDUFA Date for Iluvien (PSDV, $5.07)Tuesday, October 8, 2013 · 9:29 am |
|
How Iluvien May Benefit Alimera and pSivida (PSDV, $3.25)Friday, May 31, 2013 · 1:22 pm |
|
|
There are 9 reports on file. |
